{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T17:50:38Z","timestamp":1777225838270,"version":"3.51.4"},"reference-count":30,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2019,3,12]]},"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1136\/ejhpharm-2018-001806","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T17:16:09Z","timestamp":1557249369000},"page":"350-354","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis"],"prefix":"10.1136","volume":"27","author":[{"given":"Borja","family":"Marcos Ribes","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hospital Universitari Sant Joan d'Alacant, Sant Joan d'Alacant, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 N","family":"Sancho-Chust","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Hospital Universitari Sant Joan d'Alacant, Sant Joan d'Alacant, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Talens","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Universitari Sant Joan d'Alacant, Sant Joan d'Alacant, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Arlandis","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Hospital Universitari Sant Joan d'Alacant, Sant Joan d'Alacant, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Herraiz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Universitari Sant Joan d'Alacant, Sant Joan d'Alacant, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eusebi","family":"Chiner","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Hospital Universitari Sant Joan d'Alacant, Sant Joan d'Alacant, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Aznar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Universitari Sant Joan d'Alacant, Sant Joan d'Alacant, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"2025090702532923000_27.6.350.1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.arbres.2013.03.011","article-title":"Normativa sobre El diagn\u00f3stico Y tratamiento de la fibrosis pulmonar idiop\u00e1tica","volume":"49","author":"Xaubet","year":"2013","journal-title":"Arch Bronconeumol"},{"key":"2025090702532923000_27.6.350.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00185114"},{"issue":"3-b Suppl","key":"2025090702532923000_27.6.350.3","first-page":"S17","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis","volume":"23","author":"Fisher","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2025090702532923000_27.6.350.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2025090702532923000_27.6.350.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01758-2"},{"key":"2025090702532923000_27.6.350.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2025090702532923000_27.6.350.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401739"},{"key":"2025090702532923000_27.6.350.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200211-1311OC"},{"key":"2025090702532923000_27.6.350.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00155108"},{"key":"2025090702532923000_27.6.350.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201184"},{"key":"2025090702532923000_27.6.350.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0840OC"},{"key":"2025090702532923000_27.6.350.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207011"},{"key":"2025090702532923000_27.6.350.13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-2572"},{"key":"2025090702532923000_27.6.350.14","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (capacity): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"The Lancet"},{"key":"2025090702532923000_27.6.350.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025090702532923000_27.6.350.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025090702532923000_27.6.350.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0894CI"},{"key":"2025090702532923000_27.6.350.18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000479976","article-title":"An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (recap)","volume":"94","author":"Costabel","year":"2017","journal-title":"Respiration"},{"key":"2025090702532923000_27.6.350.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005209"},{"key":"2025090702532923000_27.6.350.20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2169\/internalmedicine.55.5272","article-title":"Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis","volume":"55","author":"Bando","year":"2016","journal-title":"Intern Med"},{"key":"2025090702532923000_27.6.350.21","doi-asserted-by":"crossref","unstructured":"Hughes G , Toellner H , Morris H , et al . Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med 2016;5. doi:doi:10.3390\/jcm5090078. [Epub ahead of print: 02 Sep 2016].","DOI":"10.3390\/jcm5090078"},{"key":"2025090702532923000_27.6.350.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.04.010"},{"key":"2025090702532923000_27.6.350.23","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2169\/internalmedicine.0559-17","article-title":"The efficacy and safety of long-term pirfenidone therapy in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Ogawa","year":"2018","journal-title":"Intern Med"},{"key":"2025090702532923000_27.6.350.24","doi-asserted-by":"crossref","unstructured":"Salih GN , Shaker SB , Madsen HD , et al . Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J 2016;3.doi:10.3402\/ecrj.v3.32608","DOI":"10.3402\/ecrj.v3.32608"},{"key":"2025090702532923000_27.6.350.25","first-page":"327","article-title":"Real-life experience with pirfenidone in idiopathic pulmonary fibrosis","volume":"41","author":"Yan","year":"2018","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"2025090702532923000_27.6.350.26","doi-asserted-by":"crossref","unstructured":"Tzouvelekis A , Karampitsakos T , Ntolios P , et al . Longitudinal \u201creal-world\u201d outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece. Front Med 2017;4.doi:10.3389\/fmed.2017.00213","DOI":"10.3389\/fmed.2017.00213"},{"key":"2025090702532923000_27.6.350.27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pupt.2017.08.011","article-title":"Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: A real-world observational study","volume":"46","author":"Tzouvelekis","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"2025090702532923000_27.6.350.28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/resp.13024","article-title":"Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions","volume":"22","author":"Galli","year":"2017","journal-title":"Respirology"},{"key":"2025090702532923000_27.6.350.29","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00011514"},{"key":"2025090702532923000_27.6.350.30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14728214.2018.1471465","article-title":"An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis","volume":"23","author":"Aryal","year":"2018","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2018-001806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:53:38Z","timestamp":1757238818000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2018-001806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,10,23]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/ejhpharm-2018-001806"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2018-001806","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]}}}